PharmaBlock Sciences (Nanjing), Inc.

Shenzhen Stock Exchange 300725.SZ

PharmaBlock Sciences (Nanjing), Inc. Return on Assets (ROA) for the year ending December 31, 2023: 3.87%

PharmaBlock Sciences (Nanjing), Inc. Return on Assets (ROA) is 3.87% for the year ending December 31, 2023, a -40.17% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

PharmaBlock Sciences (Nanjing), Inc. Return on Assets (ROA) for the year ending December 31, 2022 was 6.46%, a -53.42% change year over year.
PharmaBlock Sciences (Nanjing), Inc. Return on Assets (ROA) for the year ending December 31, 2021 was 13.87%, a 82.67% change year over year.
PharmaBlock Sciences (Nanjing), Inc. Return on Assets (ROA) for the year ending December 31, 2020 was 7.60%, a -48.60% change year over year.
PharmaBlock Sciences (Nanjing), Inc. Return on Assets (ROA) for the year ending December 31, 2019 was 14.78%, a -15.67% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

Shenzhen Stock Exchange: 300725.SZ

PharmaBlock Sciences (Nanjing), Inc.

CEO	Dr. Minmin Yang Ph.D.
IPO Date	Nov. 10, 2017
Location	China
Headquarters	10 Xuefu Road
Employees	2,455
Sector	Health Care
Industries Pharmaceuticals Chemicals & Advanced Materials Petrochemicals

Description

PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial production. It primarily businesses include building blocks collection, supplying from discovery, development to commercial; building blocks driven libraries for drug discovery; development and manufacturing of RSMs, intermediates, APIs, and drug products for drug development and commercial. The company was founded in 2006 and is based in Nanjing, the People's Republic of China.

Key trends

Past 5 years